TB-500 (Thymosin Beta-4 fragment)

TB-500 is a synthetic peptide derived from the highly conserved C-terminal region of Thymosin Beta-4 (Tβ4), a ubiquitous intracellular protein encoded by the TMSB4X gene and found in virtually all nucleated human cells. The full-length Tβ4 molecule is a 43-amino-acid polypeptide; TB-500 isolates the actin-binding domain — specifically the LKKTETQ sequence — which is understood to be responsible for much of the parent molecule's biological activity. It belongs to the Thymosin peptide family and is distinct from Thymosin Alpha-1, which operates primarily on immune signaling rather than tissue repair. TB-500 is sold exclusively as a lyophilized research chemical and is not approved for human use by the FDA, MHRA, EMA, or TGA.

The primary proposed mechanism of TB-500 centers on its interaction with G-actin (globular actin), the monomeric form of actin that polymerizes to form the cytoskeletal filaments essential for cell motility. By sequestering G-actin and modulating the actin-to-thymosin ratio within cells, Tβ4 and its active fragment are understood to promote cell migration — particularly of keratinocytes, endothelial cells, and myoblasts — into sites of injury. Research also indicates involvement in downregulating inflammatory cytokines, upregulating matrix metalloproteinases involved in tissue remodeling, and stimulating angiogenesis through promotion of endothelial cell migration. Some animal studies have additionally noted potential neurogenic activity in models of brain and spinal cord injury, though this mechanism requires substantially more investigation before conclusions can be drawn.

The evidence base for TB-500 is predominantly preclinical. Animal studies — spanning rodent, equine, and porcine models — have demonstrated accelerated wound closure, improved cardiac function following myocardial infarction, reduced fibrosis, and enhanced tendon repair. Equine sports medicine has provided a meaningful body of field-use data, as Thymosin Beta-4 and TB-500 have been used in racing horses, resulting in regulatory bans in competitive equestrian sport. Human clinical data is limited: Regenerx Biopharmaceuticals conducted Phase I and Phase II trials of full-length Tβ4 (not TB-500 specifically) for chronic cutaneous wounds and dry eye disease, with Phase II data from a 2012 trial (n=72) suggesting modest but statistically non-significant improvement in wound healing endpoints. No published randomized controlled trials exist for TB-500 as a distinct synthetic fragment administered via injection in humans. The majority of recovery and injury anecdotal reports circulating in athletic and biohacking communities are user self-reports, not controlled evidence. These should be interpreted accordingly.

Dosing ranges reported in the scientific literature and equine veterinary research typically fall between 2–2.5 mg administered two to three times per week during an initial loading phase, followed by a maintenance phase of 2 mg once weekly or biweekly. Some human self-report communities reference protocols ranging from 2.0 to 5.0 mg per week total, divided across injections. These figures are reported strictly in research and observational contexts — they do not constitute a dosing recommendation, and no safe or efficacious dose for human use has been established in peer-reviewed clinical trials. This content is for educational purposes only and does not constitute medical advice.

In terms of legal status, TB-500 occupies regulatory gray territory in the United States — it is not a scheduled controlled substance under the DEA but is also not approved for human use, making it legal to purchase for in vitro or laboratory research purposes only. In the UK, it is similarly unscheduled but falls under general medicines legislation if sold for human use without authorization. In Australia, TB-500 is subject to TGA scheduling, where unapproved peptides are treated as prescription-only substances (Schedule 4) when intended for human therapeutic use, making unregulated sourcing legally problematic. WADA prohibits Thymosin Beta-4 and its fragments under the Prohibited List (S2 – Peptide Hormones, Growth Factors, Related Substances), meaning any athlete subject to anti-doping controls should treat TB-500 as a banned substance regardless of jurisdiction. Sourcing considerations are significant: reputable vendors should provide HPLC and mass spectrometry COAs from third-party laboratories confirming peptide identity, purity (ideally >98%), and absence of bacterial endotoxins. Lyophilized powder supplied in sealed vials with lot numbers and clear reconstitution guidance is the baseline expectation for a credible research-grade supplier.